CUVLNasdaqAmerican Depositary ReceiptsFiscal year ends June 30Also trades as CLVLF
Clinuvel Pharmaceuticals Ltd
$5.24+0.00 (+0.10%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Clinuvel Pharmaceuticals has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Clinuvel Pharmaceuticals filed with the SEC
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
response in vitiligo: new cases from the CUV105 trial presented to EADV
EX-99.1 to Form 6-K
administration device for controlled-release formulations
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Annual Results – Investor Webinar
EX-99.1 to Form 6-K
CUVL | Börse Frankfurt: UR9
EX-99.1 to Form 6-K
CUV | Nasdaq : CUVL | Börse Frankfurt: UR9
EX-99.1 to Form 6-K
CUV | Nasdaq : CUVL | Börse Frankfurt: UR9
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
implements strategic reorganisation to refocus on U.S. markets
EX-99.1 to Form 6-K
ADS commences trading on Nasdaq
EX-99.1 to Form 6-K
ADS to commence trading on Nasdaq
EX-99.1 to Form 6-K